- Conditions
- Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
- Interventions
- Clinical Observation, Cyclophosphamide, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Prednisone, Therapeutic Immune Globulin
- Other · Drug · Procedure + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 8 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2022
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 385–408
of 5,388
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- Oxaliplatin
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 8
- States / cities
- Tucson, Arizona • New Haven, Connecticut • Miami Beach, Florida + 5 more
- Conditions
- ANCA-associated Vasculitis
- Interventions
- CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids, CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoids, Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 39
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 36 more
- Conditions
- Epilepsy
- Interventions
- lamotrigine
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 1 Month to 24 Months
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2006
- U.S. locations
- 41
- States / cities
- Mobile, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 36 more
- Conditions
- Alzheimer's Disease
- Interventions
- Aducanumab, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 60 Years to 85 Years
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 130
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 107 more
- Conditions
- Colorectal Cancer
- Interventions
- immunoenzyme technique, laboratory biomarker analysis
- Other
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- Not listed
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Sleep Onset Latency
- Interventions
- Amber Tinted Glasses, Clear Glasses, Smart Lightbulbs
- Device
- Lead sponsor
- University of Arizona
- Other
- Eligibility
- 60 Months to 83 Months
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Tucson, Arizona
- Conditions
- Major Depressive Disorder, Depression
- Interventions
- REL-1017, Placebo
- Drug
- Lead sponsor
- Levomecor Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 70
- States / cities
- Homewood, Alabama • Chandler, Arizona • Phoenix, Arizona + 59 more
- Conditions
- Acne Vulgaris
- Interventions
- 50 mg P005672-HCl, Placebo, 100 mg P005672-HCl
- Drug
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 285 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 38
- States / cities
- Mobile, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 34 more
- Conditions
- Diabetes, Diabetes Mellitus, Type 1
- Interventions
- insulin human, insulin lispro, insulin aspart
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 378 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2004
- U.S. locations
- 76
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more
- Conditions
- Ulcerative Colitis
- Interventions
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,027 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 233
- States / cities
- Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 205 more
- Conditions
- Macular Degeneration
- Interventions
- IMT - Implantable Miniature Telescope
- Device
- Lead sponsor
- VisionCare, Inc.
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • Irvine, California • Los Altos, California + 24 more
- Conditions
- Menorrhagia, Heavy Menstrual Bleeding
- Interventions
- Tranexamic acid tablets, Placebo tablets
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 52
- States / cities
- Tucson, Arizona • Little Rock, Arkansas • Carmichael, California + 46 more
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Moderate to Very Severe COPD
- Interventions
- Aclidinium Bromide, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 40 Years to 130 Years
- Enrollment
- 3,635 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 433
- States / cities
- Birmingham, Alabama • Florence, Alabama • Foley, Alabama + 334 more
- Conditions
- Prostate Cancer
- Interventions
- Relugolix, Leuprolide Acetate
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 387 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 108
- States / cities
- Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 83 more
- Conditions
- Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIA Distal Bile Duct Cancer AJCC v8, Stage IIIA Gallbladder Cancer AJCC v8, Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8, Stage IIIB Distal Bile Duct Cancer AJCC v8, Stage IIIB Gallbladder Cancer AJCC v8, Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Stage IVA Gallbladder Cancer AJCC v8, Stage IVB Gallbladder Cancer AJCC v8, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
- Interventions
- Cisplatin, Gemcitabine Hydrochloride, Nab-paclitaxel
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 692
- States / cities
- Anchorage, Alaska • Goodyear, Arizona • Kingman, Arizona + 448 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Pembrolizumab, Placebo
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 959 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 24
- States / cities
- Gilbert, Arizona • Tucson, Arizona • Duarte, California + 18 more
- Conditions
- Pancreatic Neuroendocrine Tumor (pNET), Extra-Pancreatic Neuroendocrine Tumor (epNET)
- Interventions
- Zanzalintinib, Everolimus
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 440 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
- Conditions
- Diabetes Mellitus
- Interventions
- SYR-472, Placebo, Sitagliptin
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 105
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 102 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- UBX0101, Placebo
- Drug · Other
- Lead sponsor
- Unity Biotechnology, Inc.
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation
- Interventions
- AXS-05, Placebo
- Drug
- Lead sponsor
- Axsome Therapeutics, Inc.
- Industry
- Eligibility
- 65 Years to 90 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 53
- States / cities
- Peoria, Arizona • Tempe, Arizona • Tucson, Arizona + 43 more
- Conditions
- Macular Degeneration
- Interventions
- TAC-PF, Triamcinolone Acetonide
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 23
- States / cities
- Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
- Conditions
- NASH With Fibrosis, MASH With Fibrosis
- Interventions
- Efruxifermin, Placebo
- Drug
- Lead sponsor
- Akero Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 198
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 160 more
- Conditions
- Vaginal Atrophy
- Interventions
- Placebo, DHEA
- Drug
- Lead sponsor
- EndoCeutics Inc.
- Industry
- Eligibility
- 40 Years to 75 Years · Female only
- Enrollment
- 255 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 24
- States / cities
- Montgomery, Alabama • Tucson, Arizona • Sacramento, California + 20 more